Akari Therapeutics
AKTX | NASDAQ
$8.24
+$0.24 (+3.00%)
At close: Oct 30, 2026, 4:00 PM ET
$8.07
-$0.17 (-2.10%)
Pre-market:
Nov 2, 2026, 7:28 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -17.28M | -21.64M | -16.81M | -23.09M | -17.21M | -17.98M |
Interest Income | 1K | 8K | 82K | 45.94K | 10.6K | 13K |
Pretax Income | -18.3M | -19.79M | -10.01M | -17.75M | -17.42M | -17.08M |
Net Income | -17.3M | -19.79M | -10.01M | -17.75M | -17.42M | -17.08M |
Selling & General & Admin | 9.28M | 9.66M | 11.36M | 13.53M | 8.08M | 9.16M |
Research & Development | 2.82M | 6.98M | 8.02M | 9.56M | 9.13M | 12.19M |
Other Expenses | 5.18M | 5M | -2.57M | n/a | n/a | -3.37M |
Operating Expenses | 17.28M | 21.64M | 16.81M | 23.09M | 17.21M | 17.98M |
Interest Expense | 949K | -244K | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 17.28M | 21.64M | 16.81M | 23.09M | 17.21M | 17.98M |
Income Tax Expense | -1M | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 21.04K | 5.97K | 2.45K | 1.56K | 1.07K | 427 |
Shares Outstanding (Diluted) | 21.04K | 5.97K | 2.45K | 1.56K | 1.07K | 789 |
EPS (Basic) | -20.8K | -132.8K | -163.2K | -455.2K | -649.6K | -896K |
EPS (Diluted) | -20.8K | -132.8K | -163.2K | -455.2K | -649.6K | -896K |
EBITDA | -17.35M | -19.53M | -10M | -17.74M | -17.42M | -17.97M |
EBIT | -17.35M | -19.55M | -10.01M | -17.75M | -17.42M | -17.98M |
Depreciation & Amortization | n/a | 14K | 4K | 4K | 4.13K | 8.91K |
Add to Watchlist
Select watchlists to add or remove AKTX